bluebird bio Stock News

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

The submission of an application for idecabtagene vicleucel comes shortly after Bristol-Myers Squibb filed for approval of another CAR-T, lisocabtagene maraleucel, in an aggressive form of lymphoma. T

Success in clinical trials doesn't guarantee success on the market.

Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug bet with shareholders that was a sweetener following its

Bristol-Myers Squibb Co:

Bristol-Myers Squibb (NYSE:BMY) and collaboration partner bluebird bio (NASDAQ:BLUE) announce the filing of a U.S. marketing application for idecabtagene vicleucel (bb2121) for the treatment of adult

Bristol-Myers, Bluebird Bio submit BLA to FDA for for idecabtagene vicleucel BMY BLUE

Bristol Myers Squibb & bluebird bio Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA

Market forces rained on the parade of bluebird bio, Inc. (NASDAQ:BLUE) shareholders today, when the analysts...

bluebird bio (NASDAQ:BLUE) had its target price lowered by BMO Capital Markets from $132.00 to $107.00 in a research note released on Friday morning, The Fly reports. The brokerage currently has an ou

William Blair reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Friday morning, AnalystRatings.com reports. A number of other analysts have

ElevateBio CEO David Hallal.